[Sustained disease control with sacituzumab govitecan in a patient with HR+/HER2- metastatic breast cancer resistant to endocrine therapy, with a high tumour burden and limited benefit from standard chemotherapy.].
- DOI
- 10.1701/4802.48291
- Published
- 2026 Nov
- Container
- Recenti progressi in medicina
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1701/4802.48291,
title = {[Sustained disease control with sacituzumab govitecan in a patient with HR+/HER2- metastatic breast cancer resistant to endocrine therapy, with a high tumour burden and limited benefit from standard chemotherapy.].},
author = {Scagnoli S},
year = {2026},
journal = {Recenti progressi in medicina},
doi = {10.1701/4802.48291},
url = {https://doi.org/10.1701/4802.48291}
}RIS
TY - JOUR TI - [Sustained disease control with sacituzumab govitecan in a patient with HR+/HER2- metastatic breast cancer resistant to endocrine therapy, with a high tumour burden and limited benefit from standard chemotherapy.]. AU - Scagnoli S PY - 2026 JO - Recenti progressi in medicina DO - 10.1701/4802.48291 UR - https://doi.org/10.1701/4802.48291 ER -
APA
S, S. (2026). [Sustained disease control with sacituzumab govitecan in a patient with HR+/HER2- metastatic breast cancer resistant to endocrine therapy, with a high tumour burden and limited benefit from standard chemotherapy.].. Recenti progressi in medicina. https://doi.org/10.1701/4802.48291
Source records
- pubmed · retrieved 2026-11-10T06:23:34.206Z